Stockscreener 앱 받기
3.69
4.24%
0.15
시장 영업 전:
3.69
전일 마감가:
$3.54
열려 있는:
$3.51
하루 거래량:
41,041
Relative Volume:
0.81
시가총액:
$34.62M
수익:
$2.57M
순이익/손실:
$-13.54M
주가수익비율:
-0.6603
EPS:
-5.5882
순현금흐름:
$-23.50M
1주 성능:
+15.31%
1개월 성능:
+22.19%
6개월 성능:
-12.56%
1년 성능:
-86.72%
1일 변동 폭
$3.42
$3.755
1주일 범위
$2.995
$3.755
52주 변동 폭
$2.75
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.69 | 34.62M | 2.57M | -13.54M | -23.50M | -5.5882 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
MSN Money - MSN
Tvardi Therapeutics Files $200 Million Mixed Shelf - Moomoo
Tvardi Therapeutics (NASDAQ: TVRD) registers $200M shelf, $12.5M ATM - Stock Titan
Is Tvardi Therapeutics (TVRD) stock breaking out | Q4 2025: EPS Misses EstimatesInvestment Signal Network - Newser
Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN
TVRD Price Today: Tvardi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Tvardi Therapeutics posts 18.3% downside EPS miss amid clinical trial costsEarnings Forecast - Newser
Tvardi Therapeutics (NASDAQ: TVRD) outlines 2026 votes on board, pay and auditors - Stock Titan
Barclays downgrades Tvardi Therapeutics (TVRD) - MSN
Tvardi Therapeutics Shares Drop After Downgrade From Barclays - Moomoo
Barclays Downgrades Tvardi Therapeutics to Underweight From Equalweight, Adjusts Price Target to $3 From $4 - Moomoo
Barclays cuts Tvardi Therapeutics stock rating on funding concerns - Investing.com
Barclays cuts Tvardi Therapeutics stock rating on funding concerns By Investing.com - Investing.com Canada
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Unlocking 140% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Pulmonary Fibrosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeut - Barchart.com
Published on: 2026-04-13 19:29:33 - baoquankhu1.vn
Weekly Trades: What hedge funds are buying Tvardi Therapeutics IncPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
TVRD Options Volatility — NASDAQ:TVRD - TradingView
Portfolio Shifts: What hedge funds are buying Tvardi Therapeutics IncTrade Entry Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Analysis Recap: Is Tvardi Therapeutics Inc attractive at current valuation2026 Highlights & Entry and Exit Point Strategies - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen - Defense World
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - Sahm
BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD) - The Globe and Mail
Barclays Lowers Price Target for Tvardi Therapeutics (TVRD) | TV - GuruFocus
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development - TipRanks
Tvardi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Tvardi Therapeutics (TVRD) Sees Price Target Cut by Piper Sandler | TVRD Stock News - GuruFocus
Piper Sandler cuts Tvardi Therapeutics price target on trial timing By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock - Investing.com
Piper Sandler cuts Tvardi Therapeutics price target on trial timing - Investing.com
Tvardi Therapeutics (NASDAQ: TVRD) registers 2,084,117 resale shares; clinical updates - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment - Stock Titan
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update - Bitget
Tvardi: Q4 Earnings Snapshot - Barchart.com
Tvardi Therapeutics (NASDAQ: TVRD) outlines STAT3 trial plans - Stock Titan
Tvardi Therapeutics Inc (TVRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):